First in Human Dose Escalation of M3258 as a Single Agent and Expansion Study of M3258 in Combination With Dexamethasone

Stopped early · Phase 1

Conditions studied: Multiple Myeloma

In brief

The purpose of this study was to determine the safety, tolerability, pharmacokinetics, pharmacodynamics and early efficacy signs of M3258 as a single agent and co-administered with dexamethasone in participants with Relapsed Refractory Multiple Myeloma (RRMM).

Key facts

Study ID

NCT04075721

Run by

EMD Serono Research & Development Institute, Inc.

People needed

10

Starts

2019-09-26

Expected to finish

2021-04-01

Last updated by the study team

2023-03-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participants having Eastern Co-operative Oncology Group (ECOG) Performance Status less than or equals to (<=) 1
• Adequate hematological, hepatic and renal function as defined in the protocol
• Participant must have measurable disease of Multiple Myeloma (MM) and received greater than (>) 3 prior lines of therapy for MM including a Proteasome Inhibitors (PI), an Immunomodulatory Imide Drug (IMiD) and an anti-CD38 mAb or who are refractory to at least PI agent (carfilzomib or bortezomib) and IMiD according to the International Myeloma Working Group (IMWG) criteria
• Participant must have documented evidence progressive disease as defined by the IMWG criteria either on or after their last regimen
• Other protocol defined inclusion criteria could apply

You may not qualify if…

• Any condition, including any uncontrolled disease state that in the Investigator's opinion constitutes an inappropriate risk or a contraindication for participation in the study or that could interfere with the study objectives, conduct, or evaluation.
• An active second malignancy or evidence of disease of cancer (other than MM) before the date of enrollment (exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or malignancy that in the opinion of the Investigator, with concurrence with the Sponsor's medical monitor, is considered cured with minimal risk of recurrence within 3 years).
• Cerebrovascular accident/stroke (< 6 months prior enrollment) or neurologic instability per clinical evaluation due to tumor involvement of the Central Nervous System
• Diagnosis of fever within 1 week prior to study intervention administration
• Part B: Participants planning to undergo a stem cell transplant should not be enrolled to reduce disease burden prior to transplant.
• Other protocol defined exclusion criteria could apply

Where it is running

• Colorado Blood Cancer Institute — Denver, Colorado, United States
• Georgetown University Medical Center- Research Parent — Washington D.C., District of Columbia, United States
• Hackensack University Medical Center — Hackensack, New Jersey, United States
• Sarah Cannon Research Institute — Nashville, Tennessee, United States
• Centre Hospitalier Regional Universitaire de Lille — Lille, France
• CHU de Nantes — Nantes, France
• CHU de Poitiers — Vauvert, France

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.